Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 0.39% is 100% above its 5-year average of -84.55%, near the high end of its 5-year range (-204.39%–2.18%).
102.42% above its 12-month average of -16.14%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 1.95%.
RETURN ON ASSETS (ROA)
0.39%
RETURN ON ASSETS (ROA) AVG TTM
-16.14%
RETURN ON ASSETS (ROA) AVG 3Y
-90.03%
RETURN ON ASSETS (ROA) AVG 5Y
-84.55%
RETURN ON ASSETS (ROA) AVG 10Y
-136.62%
RETURN ON ASSETS (ROA) AVG 15Y
-87.09%
RETURN ON ASSETS (ROA) AVG 20Y
-79.32%
CURRENT VS TTM AVG
+102.42%
CURRENT VS 3Y AVG
+100.43%
CURRENT VS 5Y AVG
+100.46%
CURRENT VS 10Y AVG
+100.29%
CURRENT VS 15Y AVG
+100.45%
CURRENT VS 20Y AVG
+100.49%
SECTOR MEDIAN · HEALTHCARE
-29.15%
median of 609 covered companies
CURRENT VS SECTOR MEDIAN
+101.34%
vs the sector median at left
Delcath Systems, Inc.
Market Cap
$533.70M
Return on Assets (ROA)
0.39%
TTM Avg
-16.14%
3Y Avg
-90.03%
5Y Avg
-84.55%
Market Cap
$524.47M
Return on Assets (ROA)
-89.18%
TTM Avg
-100.15%
3Y Avg
-92.96%
5Y Avg
-79.13%
Market Cap
$522.26M
Return on Assets (ROA)
-16.69%
TTM Avg
-61.13%
3Y Avg
-63.72%
5Y Avg
-100.27%
Market Cap
$545.32M
Return on Assets (ROA)
-124.45%
TTM Avg
-92.75%
3Y Avg
-98.77%
5Y Avg
-98.11%
Market Cap
$549.58M
Return on Assets (ROA)
-42.15%
TTM Avg
-50.20%
3Y Avg
-44.84%
5Y Avg
-47.93%
Market Cap
$550.77M
Return on Assets (ROA)
-20.89%
TTM Avg
7.49%
3Y Avg
-5.84%
5Y Avg
-12.60%
Market Cap
$554.00M
Return on Assets (ROA)
-37.16%
TTM Avg
-32.95%
3Y Avg
-32.95%
5Y Avg
-32.95%
Market Cap
$513.41M
Return on Assets (ROA)
-17.40%
TTM Avg
-49.85%
3Y Avg
-45.66%
5Y Avg
-41.17%
Market Cap
$511.25M
Return on Assets (ROA)
-13.22%
TTM Avg
-17.80%
3Y Avg
-57.37%
5Y Avg
-51.87%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Delcath Systems, Inc. (DCTH) | $533.70M | 0.39% | -16.14% | -90.03% | -84.55% |
| Crescent Biopharma, Inc. (CBIO)vs › | $524.47M | -89.18% | -100.15% | -92.96% | -79.13% |
| Immix Biopharma, Inc. (IMMX)vs › | $522.26M | -16.69% | -61.13% | -63.72% | -100.27% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $545.32M | -124.45% | -92.75% | -98.77% | -98.11% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $549.58M | -42.15% | -50.20% | -44.84% | -47.93% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $550.77M | -20.89% | 7.49% | -5.84% | -12.60% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $554.00M | -37.16% | -32.95% | -32.95% | -32.95% |
| Altimmune, Inc. (ALT)vs › | $513.41M | -17.40% | -49.85% | -45.66% | -41.17% |
| Monopar Therapeutics Inc. (MNPR)vs › | $511.25M | -13.22% | -17.80% | -57.37% | -51.87% |
| 908 Devices Inc. (MASS)vs › | $511.20M | -17.46% | -32.28% | -24.08% | -18.67% |
ROA
0.4%
ROE
0.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 2.18% |
| 2024-12-31 | -34.45% |
| 2023-12-31 | -123.48% |
| 2022-12-31 | -204.39% |
| 2021-12-31 | -77.43% |
| 2020-12-31 | -69.74% |
| 2019-12-31 | -62.48% |
| 2018-12-31 | -280.86% |
| 2017-12-31 | -507.67% |
| 2016-12-31 | -51.00% |
| 2015-12-31 | -93.46% |
| 2014-12-31 | -73.14% |
| 2013-12-31 | -81.74% |
| 2012-12-31 | -170.20% |
| 2011-12-31 | -87.64% |
| 2010-12-31 | -92.30% |
| 2009-12-31 | -59.92% |
| 2008-12-31 | -60.44% |
| 2007-12-31 | -20.23% |
| 2006-12-31 | -124.97% |
| 2005-12-31 | -22.16% |
| 2004-12-31 | -44.43% |
| 2003-12-31 | -92.59% |
| 2002-12-31 | -99.73% |
| 2001-12-31 | -55.12% |
| 2000-12-31 | -16.18% |
| 1999-12-31 | -95.00% |
| 1998-12-31 | 0.00% |
